Name | Title | Contact Details |
---|
Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention of counterfeiting and diversion. We have manufacturing facilities in Hawaii, engineering offices in California, and business development offices in Pennsylvania, Texas and Hong Kong. TruTag`s early technology research was funded in part by the U.S. Army Medical Research division. The company is supported by venture capital firms and strategic corporate investors.
AltaThera Pharmaceuticals is a Chicago-based specialty pharmaceutical company focused on identifying, acquiring, developing, and commercializing therapies addressing unmet medical needs of critical care patients and those with severe, and often rare, disorders for which few effective treatments are available.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of today`s biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible. Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done. This page isn`t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.